Mortality risk with sulphonylureas compared to metformin

Holden, Sarah and Currie, Craig 2014. Mortality risk with sulphonylureas compared to metformin. Diabetes, Obesity and Metabolism 16 (10) , pp. 885-890. 10.1111/dom.12280

Full text not available from this repository.

Abstract

Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people with type 2 diabetes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Wiley and Blackwell
ISSN:	1462-8902
Date of Acceptance:	11 February 2014
Last Modified:	27 Mar 2019 12:15
URI:	https://orca.cardiff.ac.uk/id/eprint/79062

Citation Data

Cited 22 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item